Standard BioTools Inc.
LAB
$1.01
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -3.71% | -6.24% | -8.59% | -9.06% | -12.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.71% | -6.24% | -8.59% | -9.06% | -12.93% |
| Cost of Revenue | -8.77% | 3.82% | 2.86% | -5.80% | -16.94% |
| Gross Profit | 2.62% | -16.58% | -20.19% | -12.74% | -7.33% |
| SG&A Expenses | -7.35% | 6.60% | 15.19% | 15.58% | 14.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.33% | 0.35% | 4.25% | 2.40% | 2.50% |
| Operating Income | 11.02% | -7.24% | -19.60% | -16.92% | -24.98% |
| Income Before Tax | 10.01% | -6.97% | -21.74% | -9.56% | -32.04% |
| Income Tax Expenses | -12,276.13% | -7,088.19% | -1,648.15% | -945.00% | 2.65% |
| Earnings from Continuing Operations | 48.85% | 35.31% | -19.58% | -9.09% | -31.92% |
| Earnings from Discontinued Operations | 468.06% | 66.48% | 30.93% | 15.71% | -121.26% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 158.91% | 46.07% | -2.94% | -1.56% | -47.56% |
| EBIT | 11.02% | -7.24% | -19.60% | -16.92% | -24.98% |
| EBITDA | -5.33% | -37.21% | -25.69% | -20.71% | -23.08% |
| EPS Basic | 155.98% | 64.26% | 52.28% | 64.50% | 64.34% |
| Normalized Basic EPS | 22.26% | 3.78% | 27.92% | 58.29% | 66.94% |
| EPS Diluted | 155.98% | 64.26% | 52.61% | 64.87% | 64.68% |
| Normalized Diluted EPS | 22.26% | 3.78% | 27.92% | 58.29% | 66.94% |
| Average Basic Shares Outstanding | 2.66% | 8.06% | 35.62% | 82.33% | 181.50% |
| Average Diluted Shares Outstanding | 2.66% | 8.06% | 35.62% | 82.33% | 181.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |